RxDoctor Payments Data

Srilakshmi Vemulakonda, MD

Critical Care Medicine · San Jose, CANPI 1659584019

Payments from drug & device makers

$211in general payments, 2019–2025

Across 7 payments — averaging $30.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$90
  • Boehringer Ingelheim$30
  • GSK$27
  • Electromed, Inc.$18
  • Insmed, Inc.$17
  • Intuitive Surgical$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$19492%
  • Education$178%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$211 in reported general payments places this provider in the 35th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$158,405
Medicare patients
458
Services billed
1,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter601$513,693
OfevNintedanib Esylate20$182,962
Breo ElliptaFluticasone/Vilanterol296$151,549
Pirfenidone20$105,462
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr88$56,917
Bevespi AerosphereGlycopyrrolate/Formoterol Fum21$9,083
EliquisApixaban15$8,866
Wixela InhubFluticasone Propion/Salmeterol64$7,932
Fluticasone-VilanterolFluticasone/Vilanterol19$6,899
Albuterol Sulfate HfaAlbuterol Sulfate222$5,097
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,726
Montelukast Sodium180$1,764
Ventolin HfaAlbuterol Sulfate27$1,420
Pantoprazole Sodium117$1,030
Fluticasone Propionate62$695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$27$722,158985 claims
Boehringer IngelheimOfev$30$182,96220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 715 critical care medicine providers in California.

Other critical care medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →